AIM ImmunoTech Inc (AMEX: AIM) is -58.40% lower on its value in year-to-date trading and has touched a low of $0.21 and a high of $0.62 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AIM stock was last observed hovering at around $0.23 in the last trading session, with the day’s loss setting it -0.05%.
Currently trading at $0.18, the stock is -26.04% and -29.84% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.26 million and changing -20.57% at the moment leaves the stock -49.18% off its SMA200. AIM registered -59.24% loss for a year compared to 6-month loss of -55.37%. The firm has a 50-day simple moving average (SMA 50) of $0.2634 and a 200-day simple moving average (SMA200) of $0.36155.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -30.92% gain in the last 1 month and extending the period to 3 months gives it a -53.54%, and is -23.75% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 24.24% over the week and 11.72% over the month.
AIM ImmunoTech Inc (AIM) has around 26 employees, a market worth around $11.66M and $0.19M in sales. Profit margin for the company is -12594.21%. Distance from 52-week low is -13.35% and -70.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-686.04%).
with sales reaching $45k over the same period.The EPS is expected to grow by 42.22% this year, but quarterly earnings will post -25.74% year-over-year. Quarterly sales are estimated to shrink -30.77% in year-over-year returns.
AIM ImmunoTech Inc (AIM) Top Institutional Holders
33.0 institutions hold shares in AIM ImmunoTech Inc (AIM), with institutional investors hold 15.39% of the company’s shares. The shares outstanding are 63.71M, and float is at 58.21M with Short Float at 0.84%. Institutions hold 14.07% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 4.08 million shares valued at $1.52 million. The investor’s holdings represent 8.2454% of the AIM Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.99 million shares valued at $0.74 million to account for 4.021 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 0.7 million shares representing 1.4118% and valued at over $0.26 million, while GEODE CAPITAL MANAGEMENT, LLC holds 0.8108 of the shares totaling 0.4 million with a market value of $0.15 million.
AIM ImmunoTech Inc (AIM) Insider Activity
The most recent transaction is an insider purchase by Equels Thomas K, the company’s CEO & President. SEC filings show that Equels Thomas K bought 5,000 shares of the company’s common stock on Sep 16 ’24 at a price of $0.30 per share for a total of $1515.0. Following the purchase, the insider now owns 1.49 million shares.
AIM ImmunoTech Inc disclosed in a document filed with the SEC on Sep 13 ’24 that Equels Thomas K (CEO & President) bought a total of 20,000 shares of the company’s common stock. The trade occurred on Sep 13 ’24 and was made at $0.31 per share for $6160.0. Following the transaction, the insider now directly holds 1.49 million shares of the AIM stock.
Still, SEC filings show that on May 06 ’24, Equels Thomas K (CEO & President) acquired 61,729 shares at an average price of $0.41 for $25000.0. The insider now directly holds 778,184 shares of AIM ImmunoTech Inc (AIM).
